True, cannot know. But here's the rub, the last news related to CC-31244 which gad a promising study and which seems to be a good candidate for more clinical trials. Last quarter they announced that they were looking for a partner for this on this compound and of course we haven't heard anything. Why? If this is Schinazi, the founder of Pharmasset who sold to Gilead gor $11bn, why is it that nobody is interested in partnering here? (at least as far as we know)
The only news is the appointment of the interim CFO as a permanent CFO and we see that Schinazi exercised some optioms to buy stock at just over 4 cents per share.
The stock continues to be in the doldrums with market excitement over the participants seemingly non existent.
Bit disconcerting. At least the 10Q is coming.
News 
Market Data 
Discover 
